AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

BACKGROUND: Prostate cancer(PCa) is the most commonly occurring male cancer in the USA. Abiraterone or Enzalutamide have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). However, the treatment-emergent neuroendocrine PCa (t-NEPC) may develop, resulting in dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Linglong, Ye, Yubing, Zou, Ling, Lin, Jinli, Dai, Yi, Fu, Yongming, Liu, Youhong, Peng, Yuchong, Gao, Yingxue, Fu, Yuxin, Qi, Xuli, Deng, Tanggang, Zhang, Songwei, Li, Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413764/
https://www.ncbi.nlm.nih.gov/pubmed/37563661
http://dx.doi.org/10.1186/s13046-023-02776-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413764/
https://www.ncbi.nlm.nih.gov/pubmed/37563661
http://dx.doi.org/10.1186/s13046-023-02776-0

Ejemplares similares